ESC 2021: Late-breaking Science Video Collection

Published: 02 September 2021

Views:
4275
Likes:
7

Views:
4275
Likes:
7
Share:

Now Playing
Part 3 | Session 11 of 11
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Nick Curzen

Up Next

Part 4 | Session 1 Masterclass on The Global Burden of CV Disease in Women
Birgit Vogel, Harriette Van Spall

Part 1 | Session 1 View from the Thoraxcenter – What's Hot at ESC 2021 Nicolas M Van Mieghem, Joost Daemen

Part 1 | Session 2 View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up Joost Daemen, Nicolas M Van Mieghem

Part 2 | Session 1 ESC 2021 Discussion: The EMPEROR-Preserved Trial Harriette Van Spall, Stefan Anker

Part 2 | Session 2 ESC 2021 Discussion: The FIGARO-DKD Trial Bertram Pitt, Harriette Van Spall

Part 2 | Session 3 ESC 2021 Discussion: The EMPEROR-Pooled Study Milton Packer, Harriette Van Spall

Part 3 | Session 1 ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI George D Dangas

Part 3 | Session 2 SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI Adrian P Banning

Part 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI Davide Cao

Part 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation Richard Whitlock

Part 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type George D Dangas

Part 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS Hirotoshi Watanabe

Part 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH Ali Aminian

Part 3 | Session 8 RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients Harald Thune Jorstad

Part 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes Cecilia Low Wang

Part 3 | Session 10 Micra CED: 2-Year Outcomes with Leadless Pacing Jonathan Piccini

Average (ratings)

No ratings

Your rating

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In the latest episode View from the Thoraxcenter, Professor Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their concise analysis of the hot line and late-breaking trials that will be presented at ESC Congress 2021. What presentations should we look at for this weekend? Get your update on the importance of trials such as GUIDE-HF, MASTER DAPT, TOMAHAWK and many more delivered by our world-class experts, Professor Van Mieghem and Dr Joost Daemen.

2 sessions
View from the Thoraxcenter – What's Hot at ESC 2021	Watch now
View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up	Watch now

Part 2

Late-breaker Discussion Series

Host, Dr Harriette Van Spall interviews the late-breaker and hot line presenters of ESC Congress 2021.

3 sessions
ESC 2021 Discussion: The EMPEROR-Preserved Trial	Watch now
ESC 2021 Discussion: The FIGARO-DKD Trial	Watch now
ESC 2021 Discussion: The EMPEROR-Pooled Study	Watch now

Part 3

Expert Interviews

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

11 sessions
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI	Watch now
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI	Watch now
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI	Watch now
The LAAOS III Study: Surgical AFIB Ablation Evaluation	Watch now
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type	Watch now
STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS	Watch now
SPLENDOR: Metabolic Surgery and Risk of MACE in NASH	Watch now
RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients	Watch now
VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes	Watch now
Micra CED: 2-Year Outcomes with Leadless Pacing	Watch now
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes	Watch now

Part 4

Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel

In the ESC Congress 2021 episode of the Masterclass video series, host, Dr Harriette Van Spall (McMaster University, CA) meets with Dr Birgit Vogel (Icahn School of Medicine at Mount Sinai, US), one of the commissioners and first author of the "The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030" report.

1 session
Masterclass on The Global Burden of CV Disease in Women	Watch now

Faculty Biographies

Nick Curzen

Prof Curzen is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3) and joined the editorial board in November 2021.

Prof Nick Curzen (BM (hons) PhD FRCP) is a Professor of Interventional Cardiology at the University of Southampton and Honorary Consultant Cardiologist at the University Hospital Southampton NHS Foundation Trust. He is the current President of BCIS, having previously been a Council member, Education Lead, Research Lead and Honorary Secretary.

Nick specialises in coronary and aortic valve intervention.

He pursues an active research programme: Chief Investigator for RIPCORD2 and FORECAST randomised trials as well as for FFRCT RIPCORD & COMET. He also has active interests in platelet function, computer modelling of coronary stents and re-do TAVI implantation and coronary physiology. The research group contributes to many high…

View full profile